Tilray’s Medical Milestone TLRY has expressed unbridled joy at the newfound legalization of medical cannabis in the German market, lauding the German Bundestag for their progressive stance and the monumental passing of the Medical Cannabis Act.
In a groundbreaking move last Friday, Germany’s Medical Cannabis Act came into effect, propelling public health to center stage and paving the way for patients to access top-notch cannabis medicines manufactured in Germany, as highlighted in Tilray’s official statement.
Head of International and Chief Strategy Officer at Tilray Medical, Denise Faltischek, hailed the decision, emphasizing the significance of expanding treatment options for patients and enabling personalized care. Faltischek stated, “The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs.”
Tilray, a trailblazer in the medical cannabis sector, is eager to collaborate with various partners to harness the production capabilities at its cutting-edge Neumünster facility, ensuring enhanced access to premium cannabis medicines cultivated in Germany. The Neumünster site stands as one of only three cannabis cultivation sites in Germany.
The press release from Tilray reiterated their unwavering commitment to uplifting patient health, remarking on the positive impact these developments will have on the well-being of German patients. The company expressed eager anticipation for the opportunities presented by the German government and stakeholders in advancing medical cannabis access.
From humble beginnings as a licensed medical marijuana producer in Canada to establishing the GMP-certified cannabis production facilities in Europe, starting with Portugal and subsequently in Germany, Tilray Medical has cemented its reputation as a leader in medical cannabis research and manufacturing.
Tilray Medical, a major supplier of medical cannabis brands, caters to patients, healthcare providers, hospitals, pharmacies, researchers, and governments across more than 20 countries spanning five continents.
Photo: Benzinga edit with images from Kevin Woblick and Matthew Brodeur via Unsplash
